Abstract
Buprenorphine was studied for its effects on urinary output to determine if it was an agonist, partial agonist, or antagonist at the kappa receptor. Buprenorphine was a potent antagonist of bremazocine-induced urination and had no kappa agonist activity. Thus, the high affinity that buprenorphine has for the kappa receptor results in potent kappa receptor antagonist activity in vivo.
MeSH terms
-
Animals
-
Benzomorphans / pharmacology
-
Buprenorphine / pharmacology*
-
Diuresis / drug effects
-
Drug Combinations
-
Male
-
Naltrexone / analogs & derivatives
-
Naltrexone / pharmacology
-
Rats
-
Rats, Inbred Strains
-
Receptors, Opioid / classification
-
Receptors, Opioid / drug effects*
Substances
-
Benzomorphans
-
Drug Combinations
-
Receptors, Opioid
-
Buprenorphine
-
Naltrexone
-
beta-funaltrexamine
-
bremazocine